IMMUNOTHERAPY IN ADVANCED HEPATOCELLULAR CANCER
Current treatment for advanced HCC includes mainly sorafenib and more recently approved regorafenib and nivolumab, as chemotherapy has shown little benefit.
However, the modest benefit and hepatocellular cancer trial low response rate from systemic treatments suggest an increased need for new strategies.
Recent scientific advances indicate a potential hepatocellular cancer trial from immunotherapy in hepatocellular carcinoma, due to its immunogenicity.
Several trials have evaluated both immunotherapy as monotherapy and the combination with other targeted systemic treatments or local strategies. Hepatocellular cancer trial present article reviews current clinical data regarding the possible role of immunotherapy in HCC management and future directions for clinical research.
Global cancer statistics CA Cancer J Clin ; 65 2 : Early detection of liver cancer: diagnosis and management. Curr Gastroenterol Rep ; 10 1 : Known, new and emerging risk factors of hepatocellular carcinoma review.
- IMMUNOTHERAPY IN ADVANCED HEPATOCELLULAR CANCER | The Medical-Surgical Journal
Он зря мне доверился.
- (PDF) Format PDF - Jurnalul de Chirurgie | L. Miron - punctultau.ro
Presse Med ; 46 11 : Natural history of un-treated nonsurgical hepatocellular carcinoma: Rationale for the design and evaluation of therapeutic trials.
Hepatology ; 29 1 : Medicine ; 95 11 : e Sorafenib in Advanced Hepa-tocellular Carcinoma.
Miron, M. HCC incidence has doubled over the last 20 years in Europe. The management of HCC patients depends mainly on the extent and location of the tumor and the underlying liver disease.
N Engl J Med ; 4 : Regorafenib for patients with hepa-tocellular carcinoma who progressed on sorafenib treatment RESORCE : a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet ; 7 : hepatocellular cancer trial Lancet ; 24 : Cell ; 7 : Hepatocellular cancer trial genome landscapes.
Science ; : Vascular adhesion protein-1 and ICAM-1 support the adhesion of tumor-infiltrating lymphocytes to tumor endothelium in human hepatocellular carci-noma.
J Immunol ; 8 : Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy.
Verslype 1,2O. Rosmorduc 3 și P. Incidenţă şi epidemiologie Comunitatea oncologică se confruntă cu o creştere constantă a incidenţei carcinomului hepatocelular HCC, hepatocellular carcinoma .
Nat Rev Cancer ; 12 4 : Hepatology ; 59 2 : Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation. J Hepatol ; 45 2 : A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.
J Hepatol ; 59 1 : Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol ; 66 3 : Gastroenterology ; 7 : Gale M, editor.
PLoS Pathog ; 5 2 : e A randomized phase II study to assess the effectiveness of fluid therapy or intensive nutritional support on survival in patients with advanced cancer who cannot be nourished via enteral route. J Palliat Med ; Cancer Res ; 66 2 : Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer.
Nature ; : Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features. Hepatology hepatocellular cancer trial 64 6 :